RESUMO
One of the key challenges in the development of negative index metamaterials is creating a sufficiently strong magnetic response in the material. Rare-earth ions can contain a strong optical magnetic response even in the ultraviolet region of the spectrum, which can be enhanced using magneto-electric cross-coupling. Using energies, transition strengths, and linewidths from atomic structure software, along with realistic inhomogeneous broadenings and densities in a solid, we simulate a negative index scheme using a terbium crystal at a wavelength of 282 nm.
RESUMO
We propose the extension of existing molecular modulation techniques for continuous-wave optical modulation to Raman-active microresonators. Intense pump and Stokes modes inside a microresonator prepare a high coherence of the Raman transition between two ro-vibrational states. With the coherence prepared, any laser in the optical region can be coupled to the microresonator and be modulated. We perform numerical simulations which predict that these "microresonator-based molecular modulators" could have modulation efficiencies on the order of 1% at 10 THz-scale frequencies for any optical wavelength.
RESUMO
Recent studies in adult lymphoma patients have indicated a correlation between polymorphisms of Fc gamma-receptors (FcγRs, encoded by the respective FCGR genes) and the response to rituximab treatment. In vitro, cells expressing FcγRIIIa-158V mediate antibody-dependent cellular cytotoxicity (ADCC) more efficiently than cells expressing FcγRIIIa-158F. The impact of the FCGR2A-131HR polymorphism is unclear. In this study, the FCGR polymorphisms FCGR3A-158VF and FCGR2A-131HR were analyzed in pediatric patients with mature aggressive B cell non-Hodgkin lymphoma/leukemia (B-NHL). Pediatric patients received a single dose of rituximab monotherapy. Response was evaluated on day 5 followed by standard chemotherapy for B-NHL. Among 105 evaluable patients, a response to rituximab was observed in 21 % of those homozygous for FcγRIIa-131RR (5/24) compared to 48 % of patients who were HH and HR FcγRIIa-131 allele carriers (18/34 and 21/47, respectively; p = 0.044). Among patients with the FCGR3A-158 polymorphism, those homozygous for the FF genotype had a significantly favorable rituximab response rate of 59 % (22/37) compared to 32 % in patients who were FcγRIIIa-158VV and FcγRIIIa-VF allele carriers (2/9 and 20/59, respectively; p = 0.022). A stringent phase II response evaluation of children and adolescents with B-NHL after one dose of rituximab monotherapy showed a significant association between the rituximab response rate and FCGR polymorphisms. These findings support the hypothesis that FCGR polymorphisms represent patient-specific parameters that influence the response to rituximab.